Dyadic International, Inc. (NASDAQ:DYAI) has announced a fully-funded collaboration with TurtleTree Scientific to develop a number of recombinant protein growth factors which can be manufactured at high yields and at low cost in bioreactors.
The company noted that growth factors can play a critical role in tissue development and healing, including regenerative therapies, among other emerging biological processes and products.
"Growth factors are cell signaling molecules that play an important role in increasing the quality and quantities of a growing number of potential biological products that are derived from cell cultures," said Dr Ronen Tchelet, Dyadic's vice president of Research and Business Development. "We will engineer our hyper-productive C1 cell lines to develop a number of growth factors with high bioactivity and yields that can be manufactured at flexible commercial scales and at costs that we anticipate will help TurtleTree accelerate their business."
READ: Dyadic adds biotechnology veteran Patrick Lucy to its board
Dr Tchelet added: "We are very excited for the opportunity to work with TurtleTree as they position themselves as a leading innovator of novel human growth factors by applying synthetic biology to engineer C1 cells to speed the development and help lower the cost of a growing number of biological processes and products."
Max Rye, TurtleTree's co-founder and chief strategist commented: "We chose to collaborate with Dyadic to leverage their industrially proven C1 gene expression platform to help us in the development of manufacturing processes for several of our proprietary growth factors."
"Manufacturing human growth factors at large scale, and at an affordable cost, has been a challenge, which has impacted several exciting commercial processes we are targeting, including tissue healing, anti-inflammatory and other forms of regenerative medicine. It was important for us to partner with Dyadic to help us overcome this hurdle, without compromising on the safety or efficacy while lowering our capital and operating expenses. Additionally, growth factors have the potential to be applied in several other emerging and exciting applications."
Dyadic is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.
Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.
Contact the author at jon.hopkins@proactiveinvestors.com